SCHEMBL1543054

SCHEMBL1543054

COc1c(NC(=O)c2ccc(O)cc2F)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.44
CD274 Q9NZQ7 2/20 0.42
BTK Q06187 3/20 0.38
ESRRG P62508 1/20 0.37
CFTR P13569 1/20 0.37
NTRK1 P04629 1/20 0.37
SCN10A Q9Y5Y9 4/20 0.35
SCN8A Q9UQD0 3/20 0.35
ABL1 P00519 1/20 0.35
TP53 P04637 1/20 0.35
NR1H4 Q96RI1 2/20 0.34
PPARG P37231 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542476 0.90 CYP3A4 (0.44) CYP3A4CD274BTKCFTRNTRK1
SCHEMBL1542763 0.87 CD274 (0.42) CYP3A4CD274BTKESRRGNTRK1
SCHEMBL2127612 0.87 CYP3A4 (0.58) CYP3A4CD274BTKCFTRSCN10A
SCHEMBL1542564 0.82 CYP3A4 (0.43) CYP3A4CD274BTKCFTRSCN10A
SCHEMBL1542657 0.82 CYP3A4 (0.49) CYP3A4BTKABL1TP53NR1H4
SCHEMBL1543460 0.81 CYP3A4 (0.44) CYP3A4CD274BTKABL1TP53
SCHEMBL2127468 0.81 CYP3A4 (0.44) CYP3A4CD274NR1H4KDM4EALDH1A1
SCHEMBL1542748 0.80 CYP3A4 (0.47) CYP3A4CD274BTKABL1TP53
SCHEMBL2128872 0.79 CYP3A4 (0.57) CYP3A4CD274SCN10ASCN8AABL1
SCHEMBL2127623 0.79 CYP3A4 (0.53) CYP3A4CD274BTKABL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885CD274 3357/4885BTK 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.